Abstract
Passive transfer of antibodies from COVID-19 convalescent patients is being used as an experimental treatment for eligible patients with SARS-CoV-2 infections. The United States Food and Drug Administration’s (FDA) guidelines for convalescent plasma recommends target antibody titers of 160. We evaluated SARS-CoV-2 neutralizing antibodies in sera from recovered COVID-19 patients using plaque reduction neutralization tests (PRNT) at low (PRNT50) and high (PRNT90) stringency thresholds. We found that neutralizing activity increased with time post symptom onset (PSO), reaching a peak at 31-35 days PSO. At this point, the number of sera having neutralizing titers of at least 160 was ∼93% (PRNT50) and ∼54% (PRNT90). Sera with high SARS-CoV-2 antibody levels (>960 ELISA titers) showed maximal activity, but not all high titer sera contained neutralizing antibody at FDA recommended levels, particularly at high stringency. These results underscore the value of serum characterization for neutralization activity.
Competing Interest Statement
Mount Sinai Hospital is in the process of licensing assays to commercial entities based on the assays described here and has filed for patent protection.
Funding Statement
Testing at the Wadsworth Center was supported by internal funding at the New York State Department of Health. Mount Sinai Hospital is a CLIA laboratory and all the testing for patient specimens was supported by reimbursement from insurance policies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Specimens were collected with informed consent obtained from individuals in accordance with guidelines of Mount Sinai Hospital (MSH) and the Westchester County Department of Health (WCDH). Testing at the Wadsworth Center was done under a declared Public Health Emergency with a waiver from the NYSDOH Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interests – Mount Sinai Hospital is in the process of licensing assays to commercial entities based on the assays described here and has filed for patent protection.
Authors, other than those affiliated with Mount Sinai Hospital, as above, do not have a commercial or other association that might pose a conflict of interest.
This work was supported by the New York State Department of Health
This work has not been presented elsewhere.
Address correspondence and reprint requests to: Dr. William Lee, The Wadsworth Center/NYSDOH, David Axelrod Institute, 120 New Scotland Avenue, Albany, NY 12208, (telephone) 518-473-3543, (FAX) 518-486-7971, (email) william.lee{at}health.ny.gov
Data Availability
All data referred to in the manuscript is freely available.
Abbreviations used
- FDA
- Food and Drug Administration
- PRNT
- plaque reduction neutralization test
- PSO
- post-symptom onset
- COVID-19
- Coronavirus Disease 2019
- SARS-CoV-2
- Severe Acute Respiratory Syndrome coronavirus 2
- Ab
- antibody
- MN
- microneutralization
- MSH
- Mount Sinai Hospital
- WCDH
- Westchester County Department of Health
- ELISA
- enzyme-linked immunosorbent assay
- MIA
- microsphere immunoassay
- N
- nucleocapsid protein
- RBD
- receptor-binding domain of the spike protein
